Literature DB >> 21745203

Fetal surgery for myelomeningocele: progress and perspectives.

Enrico Danzer1, Mark P Johnson, N Scott Adzick.   

Abstract

Myelomeningocele (MMC), one of the most common congenital malformations, can result in severe lifelong disabilities, including paraplegia, hydrocephalus, Chiari II malformation, bowel and bladder dysfunction, skeletal deformations, and neurocognitive impairment. Experimental studies provide compelling evidence that the neurological deficits associated with MMC are not simply caused by incomplete neurulation but rather by the prolonged exposure of the vulnerable neural elements to the intrauterine environment. MMC is the first non-lethal anomaly considered for fetal surgical intervention, necessitating a careful analysis of risks and benefits. Retrospective and prospective randomized studies suggest that fetal surgery of MMC before 26 weeks of gestation may preserve neuromotor function, reverse hindbrain herniation, and reduce the need for ventriculoperitoneal shunting. However, these studies also demonstrate that fetal surgery is associated with significant maternal and fetal risks. Consequently, additional research is necessary to further elucidate the pathophysiology of MMC, to define the ideal timing and technique of fetal closure, and to evaluate the long-term implications of prenatal intervention. © The Authors. Developmental Medicine & Child Neurology
© 2011 Mac Keith Press.

Entities:  

Mesh:

Year:  2011        PMID: 21745203     DOI: 10.1111/j.1469-8749.2011.04049.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

1.  Prenatal Repair of Myelomeningocele and School-age Functional Outcomes.

Authors:  Amy J Houtrow; Elizabeth A Thom; Jack M Fletcher; Pamela K Burrows; N Scott Adzick; Nina H Thomas; John W Brock; Timothy Cooper; Hanmin Lee; Larissa Bilaniuk; Orit A Glenn; Sumit Pruthi; Cora MacPherson; Diana L Farmer; Mark P Johnson; Lori J Howell; Nalin Gupta; William O Walker
Journal:  Pediatrics       Date:  2020-02       Impact factor: 7.124

2.  Fetal Intraventricular Hemorrhage in Open Neural Tube Defects: Prenatal Imaging Evaluation and Perinatal Outcomes.

Authors:  R A Didier; J S Martin-Saavedra; E R Oliver; S E DeBari; L T Bilaniuk; L J Howell; J S Moldenhauer; N S Adzick; G G Heuer; B G Coleman
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-17       Impact factor: 3.825

3.  Anesthesia for in utero repair of myelomeningocele.

Authors:  Marla Ferschl; Robert Ball; Hanmin Lee; Mark D Rollins
Journal:  Anesthesiology       Date:  2013-05       Impact factor: 7.892

4.  Experience in shunt management on revision free survival in infants with myelomeningocele.

Authors:  Sara Al-Hakim; Andreas Schaumann; Joanna Schneider; Matthias Schulz; Ulrich-Wilhelm Thomale
Journal:  Childs Nerv Syst       Date:  2018-03-26       Impact factor: 1.475

5.  In spina bifida aperta, muscle ultrasound can quantify the "second hit of damage".

Authors:  R J Verbeek; J H van der Hoeven; N M Maurits; O F Brouwer; E W Hoving; D A Sival
Journal:  Childs Nerv Syst       Date:  2012-11-09       Impact factor: 1.475

6.  In utero therapy for congenital disorders using amniotic fluid stem cells.

Authors:  Durrgah L Ramachandra; Steven S W Shaw; Panicos Shangaris; Stavros Loukogeorgakis; Pascale V Guillot; Paolo De Coppi; Anna L David
Journal:  Front Pharmacol       Date:  2014-12-19       Impact factor: 5.810

7.  In utero repair of fetal rat myelomeningocele affects neuromuscular development in the bladder.

Authors:  Liangfeng Tang; Haijun Zhong; Hong Chen; Jian Shen; Yunli Bi; Xianmin Xiao
Journal:  Exp Ther Med       Date:  2017-08-21       Impact factor: 2.447

8.  Just choice: a Danielsian analysis of the aims and scope of prenatal screening for fetal abnormalities.

Authors:  Greg Stapleton; Wybo Dondorp; Peter Schröder-Bäck; Guido de Wert
Journal:  Med Health Care Philos       Date:  2019-12

9.  Development of a Core outcome set for fetal Myelomeningocele (COSMiC): study protocol.

Authors:  Samar Altoukhi; Clare L Whitehead; Greg Ryan; Jan Deprest; Luc Joyeux; Katie Gallagher; James Drake; Paige Church; Daphne Horn; Yenge Diambomba; Jose C A Carvalho; Tim Van Mieghem
Journal:  Trials       Date:  2020-08-21       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.